| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d595ec481a2a081fed4aa2fd4ff52d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19412dd912c6181ee37ed3af5428a60d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69cc78c1abf11b133438464ae2c05c0f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-046
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate |
2009-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8d733b2ef3311f308eb1daa12cc96d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ff3c231d9b934d3ce2bad04ec6e8572 |
| publicationDate |
2010-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010051473-A2 |
| titleOfInvention |
Identifying parathyroid hormone agonists and antagonists |
| abstract |
Provided herein are methods of screening for an agent that is a PTH agonist or antagonist. For example, provided is a method of screening for an agent that is a PTH agonist or antagonist, the method comprising contacting a cell with LRP6 and the agent to be screened, wherein the cell comprises a PTH1R, and determining the level of LRP6 binding to the PTH1R. An increased level of LRP6 binding to the PTH1R compared to a control indicates the agent is a PTH agonist.. A decreased level of LRP6 binding to the PTH1R compared to a control indicates the agent is a PTH antagonist. Also provided are methods of treating a skeletal disorder in a subject, wherein the skeletal disorder is characterized by proliferative bone growth or reduced bone density. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102608313-A |
| priorityDate |
2008-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |